BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 24507087)

  • 1. Pirfenidone inhibits fibrocyte accumulation in the lungs in bleomycin-induced murine pulmonary fibrosis.
    Inomata M; Kamio K; Azuma A; Matsuda K; Kokuho N; Miura Y; Hayashi H; Nei T; Fujita K; Saito Y; Gemma A
    Respir Res; 2014 Feb; 15(1):16. PubMed ID: 24507087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Local delivery of biodegradable pirfenidone nanoparticles ameliorates bleomycin-induced pulmonary fibrosis in mice.
    Trivedi R; Redente EF; Thakur A; Riches DW; Kompella UB
    Nanotechnology; 2012 Dec; 23(50):505101. PubMed ID: 23186914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resolution of bleomycin-induced murine pulmonary fibrosis via a splenic lymphocyte subpopulation.
    Kamio K; Azuma A; Matsuda K; Usuki J; Inomata M; Morinaga A; Kashiwada T; Nishijima N; Itakura S; Kokuho N; Atsumi K; Hayashi H; Yamaguchi T; Fujita K; Saito Y; Abe S; Kubota K; Gemma A
    Respir Res; 2018 Apr; 19(1):71. PubMed ID: 29690905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of platelet-derived growth factor/platelet-derived growth factor receptor axis in the trafficking of circulating fibrocytes in pulmonary fibrosis.
    Aono Y; Kishi M; Yokota Y; Azuma M; Kinoshita K; Takezaki A; Sato S; Kawano H; Kishi J; Goto H; Uehara H; Izumi K; Nishioka Y
    Am J Respir Cell Mol Biol; 2014 Dec; 51(6):793-801. PubMed ID: 24885373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis.
    Oku H; Shimizu T; Kawabata T; Nagira M; Hikita I; Ueyama A; Matsushima S; Torii M; Arimura A
    Eur J Pharmacol; 2008 Aug; 590(1-3):400-8. PubMed ID: 18598692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-fibrotic efficacy of nintedanib in pulmonary fibrosis via the inhibition of fibrocyte activity.
    Sato S; Shinohara S; Hayashi S; Morizumi S; Abe S; Okazaki H; Chen Y; Goto H; Aono Y; Ogawa H; Koyama K; Nishimura H; Kawano H; Toyoda Y; Uehara H; Nishioka Y
    Respir Res; 2017 Sep; 18(1):172. PubMed ID: 28915889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Netrin-1 Regulates Fibrocyte Accumulation in the Decellularized Fibrotic Sclerodermatous Lung Microenvironment and in Bleomycin-Induced Pulmonary Fibrosis.
    Sun H; Zhu Y; Pan H; Chen X; Balestrini JL; Lam TT; Kanyo JE; Eichmann A; Gulati M; Fares WH; Bai H; Feghali-Bostwick CA; Gan Y; Peng X; Moore MW; White ES; Sava P; Gonzalez AL; Cheng Y; Niklason LE; Herzog EL
    Arthritis Rheumatol; 2016 May; 68(5):1251-61. PubMed ID: 26749424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Essential roles of the CC chemokine ligand 3-CC chemokine receptor 5 axis in bleomycin-induced pulmonary fibrosis through regulation of macrophage and fibrocyte infiltration.
    Ishida Y; Kimura A; Kondo T; Hayashi T; Ueno M; Takakura N; Matsushima K; Mukaida N
    Am J Pathol; 2007 Mar; 170(3):843-54. PubMed ID: 17322370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New concepts of IL-10-induced lung fibrosis: fibrocyte recruitment and M2 activation in a CCL2/CCR2 axis.
    Sun L; Louie MC; Vannella KM; Wilke CA; LeVine AM; Moore BB; Shanley TP
    Am J Physiol Lung Cell Mol Physiol; 2011 Mar; 300(3):L341-53. PubMed ID: 21131395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of lecithinized superoxide dismutase and/or pirfenidone against bleomycin-induced pulmonary fibrosis.
    Tanaka KI; Azuma A; Miyazaki Y; Sato K; Mizushima T
    Chest; 2012 Oct; 142(4):1011-1019. PubMed ID: 22459774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pirfenidone inhibits myofibroblast differentiation and lung fibrosis development during insufficient mitophagy.
    Kurita Y; Araya J; Minagawa S; Hara H; Ichikawa A; Saito N; Kadota T; Tsubouchi K; Sato N; Yoshida M; Kobayashi K; Ito S; Fujita Y; Utsumi H; Yanagisawa H; Hashimoto M; Wakui H; Yoshii Y; Ishikawa T; Numata T; Kaneko Y; Asano H; Yamashita M; Odaka M; Morikawa T; Nakayama K; Kuwano K
    Respir Res; 2017 Jun; 18(1):114. PubMed ID: 28577568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pirfenidone attenuates bleomycin-induced pulmonary fibrosis in mice by regulating Nrf2/Bach1 equilibrium.
    Liu Y; Lu F; Kang L; Wang Z; Wang Y
    BMC Pulm Med; 2017 Apr; 17(1):63. PubMed ID: 28420366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Upregulation of RGS2: a new mechanism for pirfenidone amelioration of pulmonary fibrosis.
    Xie Y; Jiang H; Zhang Q; Mehrotra S; Abel PW; Toews ML; Wolff DW; Rennard S; Panettieri RA; Casale TB; Tu Y
    Respir Res; 2016 Aug; 17(1):103. PubMed ID: 27549302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitory effect of CXC chemokine receptor 4 antagonist AMD3100 on bleomycin induced murine pulmonary fibrosis.
    Song JS; Kang CM; Kang HH; Yoon HK; Kim YK; Kim KH; Moon HS; Park SH
    Exp Mol Med; 2010 Jun; 42(6):465-72. PubMed ID: 20498529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surfactant protein-D regulates effector cell function and fibrotic lung remodeling in response to bleomycin injury.
    Aono Y; Ledford JG; Mukherjee S; Ogawa H; Nishioka Y; Sone S; Beers MF; Noble PW; Wright JR
    Am J Respir Crit Care Med; 2012 Mar; 185(5):525-36. PubMed ID: 22198976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic administration of inhaled INS1009, a treprostinil prodrug formulation, inhibits bleomycin-induced pulmonary fibrosis in rats.
    Corboz MR; Zhang J; LaSala D; DiPetrillo K; Li Z; Malinin V; Brower J; Kuehl PJ; Barrett TE; Perkins WR; Chapman RW
    Pulm Pharmacol Ther; 2018 Apr; 49():95-103. PubMed ID: 29408757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Essential involvement of the CX3CL1-CX3CR1 axis in bleomycin-induced pulmonary fibrosis via regulation of fibrocyte and M2 macrophage migration.
    Ishida Y; Kimura A; Nosaka M; Kuninaka Y; Hemmi H; Sasaki I; Kaisho T; Mukaida N; Kondo T
    Sci Rep; 2017 Dec; 7(1):16833. PubMed ID: 29203799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis.
    Phillips RJ; Burdick MD; Hong K; Lutz MA; Murray LA; Xue YY; Belperio JA; Keane MP; Strieter RM
    J Clin Invest; 2004 Aug; 114(3):438-46. PubMed ID: 15286810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antifibrotic effects of CXCR4 antagonist in bleomycin-induced pulmonary fibrosis in mice.
    Makino H; Aono Y; Azuma M; Kishi M; Yokota Y; Kinoshita K; Takezaki A; Kishi J; Kawano H; Ogawa H; Uehara H; Izumi K; Sone S; Nishioka Y
    J Med Invest; 2013; 60(1-2):127-37. PubMed ID: 23614921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blockade of platelet-derived growth factor receptor-β, not receptor-α ameliorates bleomycin-induced pulmonary fibrosis in mice.
    Kishi M; Aono Y; Sato S; Koyama K; Azuma M; Abe S; Kawano H; Kishi J; Toyoda Y; Okazaki H; Ogawa H; Uehara H; Nishioka Y
    PLoS One; 2018; 13(12):e0209786. PubMed ID: 30596712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.